Nektar Therapeutics Stock (NKTR) Surges Into a Major Catalyst: What to Know Ahead of Today’s REZOLVE-AA Data
Nektar Therapeutics shares rose 8%–11% in pre-market trading December 16 ahead of topline results from its Phase 2b REZOLVE-AA trial in severe-to-very-severe alopecia areata. The company will release data and hold an investor call at 8:00 a.m. ET. The trial enrolled about 90 patients and tested rezpegaldesleukin against placebo, with the primary endpoint at 36 weeks.
